traneurocin
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Sep 15, 2018 (NCT03538522)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 2
- Cognition Disorders · Phase 2
- Cognitive Dysfunction · Phase 2
- Coronavirus Infections · Phase 2/Phase 3
- COVID-19 · Phase 3
- Dementia, Vascular · Phase 2
- Lewy Body Disease · Phase 2
- Neurocognitive Disorders · Phase 2
- Neurodegenerative Diseases · Phase 2
- SARS-CoV-2 · Phase 3
- Severe Acute Respiratory Syndrome · Phase 3
- Tauopathies · Phase 2
Mechanism of action
GRIA1 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04540185 | Phase 3 | Nov 1, 2020 | Biomed Industries, Inc., Coronavirus Research Institute, NeuroActiva |
| NCT04452565 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2020 | NeuroActiva |
| NCT03538522 | Phase 2 | Sep 15, 2018 | NeuroActiva, The Florey Institute of Neuroscience and Mental Health |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroActiva | For profit | 3 | 3 | 2 | 2018 |
| Biomed Industries, Inc. | For profit | 1 | 0 | 1 | 2020 |
| Coronavirus Research Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| The Florey Institute of Neuroscience and Mental Health | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1